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Superactivation of AMPA receptors by auxiliary
proteins
Anna L. Carbone1,2 & Andrew J.R. Plested1,2
Glutamate receptors form complexes in the brain with auxiliary proteins, which control their
activity during fast synaptic transmission through a seemingly bewildering array of effects.
Here we devise a way to isolate the activation of complexes using polyamines, which enables
us to show that transmembrane AMPA receptor regulatory proteins (TARPs) exert their
effects principally on the channel opening reaction. A thermodynamic argument suggests that
because TARPs promote channel opening, receptor activation promotes AMPAR-TARP
complexes into a superactive state with high open probability. A simple model based on this
idea predicts all known effects of TARPs on AMPA receptor function. This model also predicts
unexpected phenomena including massive potentiation in the absence of desensitization and
supramaximal recovery that we subsequently detected in electrophysiological recordings.
This transient positive feedback mechanism has implications for information processing in
the brain, because it should allow activity-dependent facilitation of excitatory synaptic
transmission through a postsynaptic mechanism.
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A
MPA-type glutamate receptors (AMPARs) mediate the
vast majority of the fast excitatory transmission in
the brain. Like most ion channels, native AMPARs are
macromolecular complexes of GluA subunits and accessory
proteins. Stargazin, also known as g-2, is the prototype auxiliary
subunit of AMPARs1,2. Its absence in the Stargazer mouse
provokes loss of functional synaptic receptors in cerebellar
granule cells2,3 due to interplay between several transmembrane
AMPA receptor regulatory proteins (TARPs)4. In addition to
controlling the expression and the abundance of receptors at the
postsynaptic membrane2,5,6, TARPs modulate the gating and
pharmacology of AMPARs7,8. The kinetics of AMPARs expressed
at synapses shape synaptic currents, and can determine
short-term plasticity, over timescales far exceeding the
glutamate transient from a single release event9. In principle,
any kinetic transitions that are slow enough to allow AMPAR
complexes to accumulate in different states during repetitive
activity have implications for neuronal computation and sensory
integration10.
To date, the models proposed to explain the apparently
complex effects of Stargazin on AMPARs are inconsistent8,11–13.
We devised a new method to isolate the activation of complexes,
enabling us to detect the effects of Stargazin and another type-1
TARP (g-8) that were previously missed. Using a series of
AMPAR mutants, we developed a simple kinetic mechanism for
AMPARs in complex with Stargazin. This mechanism predicts all
reported behaviour of such complexes, and some previously
unsuspected gating phenomena, establishing a general principle
for TARP modulation of AMPAR function. We propose that
TARPs exist in at least two different conformational states, and
can themselves be activated by the receptor, with implications for
synaptic transmission.
Results
Isolating complexes of AMPARs with Stargazin. We
coexpressed GluA2 homomeric receptors unedited at the Q/R site
and Stargazin in HEK cells and recorded outside out patches
including 50 mM spermine in the pipette. As previously shown14,
in the presence of intracellular polyamines, only cells expressing
both GluA2 and Stargazin showed current at þ 50mV in
response to 10mM glutamate (150±15 pA, n¼ 45). The
response of cells transfected with GluA2 only was typically
indistinguishable from the noise, because receptors that are not in
complex with TARPs are blocked by intracellular polyamines
(5±0.7 pA, n¼ 15; Fig. 1a). However, G–V relations showed that
an engineered GluA2-Stargazin tandem construct15,16 had more
profound relief of polyamine block (Fig. 1b). This difference led
us to hypothesize that in a simple cotransfection, corresponding
to almost all previously published work, the expressed
receptors were a mosaic mixture. In this mixture, some of the
receptors were associated with fewer Stargazin molecules than
others, and it is conceivable that some lacked any TARPs
whatsoever. Consistent with this idea, Stargazin showed a larger
apparent effect on the kinetics of GluA2 receptors at þ 50mV,
compared with –60mV, presumably because of more profound
voltage-dependent polyamine block in receptors with lesser
TARP content (kdes¼ 50±2 and 70±4 s 1, P¼ 0.00004,
n¼ 42 and 17; kdeact¼ 450±40 and 690±90 s 1, P¼ 0.0044,
n¼ 44 and 13; Iss¼ 30±2% and 15±2%, P¼ 0.00001, n¼ 39
and 16 for þ 50 and –60mV, respectively; Fig. 1c). A full analysis
over voltages from  60 to þ 60mV is shown in Fig. 1e,
Supplementary Fig. 1A,B and Supplementary Table 1. This
voltage dependence was not observed in the absence of polyamine
(Supplementary Fig. 1A,B and Supplementary Table 1). More
profound differences with recording potential were observed for
some of the mutants used in this study (Supplementary Fig. 1C).
Moreover, some patches at –60mV showed time-dependent
increase in the desensitization rate and concurrent reduction in
the steady-state current, possibly due to dynamic dissociation
of Stargazin from complexes during the recording16. These
time-dependent effects on kinetic properties were not observed at
þ 50mV (Supplementary Fig. 1D), presumably because only
receptors with a heavy TARP content pass appreciable ionic
current at this potential (Fig. 1b). In contrast, the kinetics of the
GluA2-Stargazin tandem, and wild-type GluA2 in the absence of
polyamine, were indistinguishable between positive and negative
potentials (Fig. 1d,e; Supplementary Fig. 1A,B and Supplementary
Table 1). These results exclude spurious voltage-dependent effects
of Stargazin or voltage-dependent gating of AMPARs within
complexes.
Although these data suggested that the currents we isolated at
positive potential were comparatively rich in TARPs, we
measured the efﬁcacy of kainate relative to that of glutamate, to
estimate the average TARP content of complexes15. At þ 50mV,
kainate efﬁcacy from cells coexpressing GluA2 and Stargazin
was indistinguishable from that of cells expressing the
GluA2-Stargazin tandem (0.38±0.05, n¼ 20 and 0.43±0.08,
n¼ 4 respectively, P¼ 0.147, Supplementary Fig. 2). However, at
–60mV, KA/Glu ratio was much more variable, and on average
less than in the tandem (0.28±0.14 and 0.35±0.03, n¼ 12 and 6,
respectively, P¼ 0.0069, Supplementary Fig. 2). By this measure,
in cells cotransfected with GluA2 and Stargazin, the complexes
that we isolated at þ 50mV were saturated with TARPs.
These results further support our hypothesis that coexpression
produces a variable, mixed population of receptors with different
levels of TARP content, and possibly some receptors that lack
TARPs altogether. Distinct from previously published work, in
subsequent experiments we enriched for complexes with a higher
TARP content, by working at þ 50mV in the presence of
intracellular polyamines. This measure mimics more closely the
synaptic receptor population, where receptors are predominantly
TARPed15. Even more importantly, by isolating complexes with
a heavy TARP content in all the subsequent experiments we
report here, we eliminated cell-to-cell variability from unequal
expression levels, enabling us to monitor effects of TARPs that, in
almost all previously published work, were diluted or essentially
absent because of a variable, unquantiﬁed background of
receptors either with few or no TARPs.
State dependence of modulation by stargazin. To investigate the
mechanism of modulation of AMPAR gating by Stargazin, we used
a panel of ligand-binding domain mutants, which spend very
different fractions of time in the active versus desensitized states in
saturating glutamate17 (Supplementary Fig. 3). All mutants tested
showed similar relief of polyamine block, measured as an increase
in the rectiﬁcation index (RI¼ Iþ 40/I 60, Supplementary Fig. 3C),
suggesting that they were all able to form complexes with
Stargazin. In any case, working at þ 50mV removed any
confounding effect of differential association of the mutants with
Stargazin. Kinetic analysis of the mutants showed that the effect of
Stargazin was correlated to the fraction of time that receptors
spend in the desensitized state. Stargazin had limited effects on the
kinetics of mutants with long-lived desensitized states, such as
GluA2 E713T, GluA2 Y768R and GluA2 E713T/Y768R. However,
coexpression with Stargazin massively increased the steady-state
current for receptors with fast recovery (and thus more
available open state), such as GluA2 R675S and GluA2 K761M
(see Supplementary Table 2 and Fig. 2a). This increase in the
steady-state current was strongly correlated to the rate of recovery
from the desensitized state (R2¼ 0.92; Fig. 2b, Supplementary
Table 2). This correlation suggested that the potentiation of
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receptor gating by Stargazin is a positive feedback mechanism that
depends on availability of the receptor in the open state.
A mechanism for AMPAR-Stargazin complexes. We previously
proposed a kinetic mechanism that recapitulates the broad
spectrum of desensitization and gating behaviour of the series of
ligand binding domain (LBD) mutants17 (Fig. 3a and Methods).
We reasoned that this mechanism should also be able to describe
the effects of Stargazin on these mutants, given appropriate
modiﬁcations. We included extra states to represent the
assumption that Stargazin itself can exist in a basal state that
has no kinetic inﬂuence on the complex, and an active state in
which the receptor has an increased channel opening rate and
mean conductance (Fig. 3b). In resting and bound states,
Stargazin was biased towards its basal state, but enforcing
microscopic reversibility required that Stargazin be promoted
towards its active state by channel opening (thus s*þ 44 sþ ,
see Methods). The open state with Stargazin active (ARS*) had
2.5-fold higher mean conductance than the basal open state
(ARs*), reﬂecting greater average occupancy of high conductance
states8,18,19. We presumed that glutamate binding rates and relief
of polyamine block were identical, whether Stargazin was active
or not. This simpliﬁed model predicted all known biophysical
properties of Stargazin-containing complexes, including larger
peak open probability and steady-state current, slower
desensitization (Fig. 3c) and higher glutamate apparent afﬁnity
(Fig. 3d). Because about 5% of the population are already
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Figure 1 | Isolating AMPAR-Stargazin complexes using intracellular polyamines. (a) Currents from GluA2 receptors alone were blocked by polyamines
and responses were indistinguishable from the noise at þ 50mV (left). Only cells coexpressing GluA2 and Stargazin showed a current at þ 50mV in the
presence of 50mM intracellular spermine (right). (b) G–V relations in the presence of intracellular spermine for peak currents evoked by 10mM glutamate
for GluA2 alone (n¼ 15), GluA2 cotransfected with Stargazin (n¼9) and GluA2-Stargazin tandem (n¼ 7). (c) Representative current responses from cells
coexpressing GluA2 and Stargazin in response to 500ms (left) and 1ms (right) applications of glutamate recorded at þ 50 or 60mV (with 50mM
intracellular spermine). Normalizing to the peak current revealed a greater apparent effect of Stargazin at þ 50mV (bottom panels; ISS¼ 20 and 12%;
kdeact¼ 700 and 1300 s 1 at þ 50mV and 60mV, respectively). (d) Currents from cells expressing the GluA2-Stargazin tandem showed no voltage
dependence (ISS¼ 18%; kdeact¼ 1,100 and 1,000 s 1 at þ 50mV and 60mV, respectively). Representative solution exchange proﬁles are shown above
the traces. (e) Voltage dependence of the rate of desensitization, the steady-state current and the deactivation rate of GluA2 cotransfected with Stargazin
(red diamonds, n¼ 10–44), GluA2-Stargazin tandem (orange circles, n¼8–25) and GluA2 alone (black squares, n¼ 10–30). Error bars represent s.e.m.
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opening to a high conductance, the mechanism also predicted the
pronounced slow component in the deactivation decays for fast
recovering mutants (Fig. 3e), and thus the lengthening of
excitatory postsynaptic currents by TARPs. Finally, a modiﬁed
version of the model predicted very well the effect of Stargazin on
currents induced by kainate, and the increase in the KA/Glu
current ratio, with only minimal modiﬁcations to allow for the
weak partial agonism of kainate (Supplementary Fig. 4).
Recovery overshoot. Our model also predicted unexpected
properties of AMPAR-Stargazin complexes, which we could
conﬁrm experimentally. First, the model predicted a surprising
overshoot in the recovery from desensitization curve for mutants
with less stable desensitized states. The model predicted transient
accumulation of complexes with higher conductance open states
during long glutamate exposures, intended to desensitize
receptors for measurements of recovery from desensitization.
Thus, the response to the second pulse could in principle exceed
that of the initial peak, producing a hump in the recovery curve if
receptors recover before this potentiating effect dissipates. In
receptors with slower recovery like GluA1, this effect should
simply make recovery from desensitization apparently faster
(Fig. 4a,b), in line with previous studies reporting an increase in
the rate of recovery from desensitization induced by Stargazin7,20.
In light of the model prediction, we hypothesized that the faster
recovery previously observed in the presence of Stargazin could
be an artefact of increased activity of the complex at the end of
long conditioning pulses used to drive the receptor into the
desensitized state in recovery protocols, rather than a true
increase in the rate of recovery. Indeed, traces recorded from
GluA2 WT and mutants with fast recovery, such as GluA2 R675S,
showed that the current recovered to a higher level than the ﬁrst
peak and then decreased to the initial level. As predicted by the
mechanism (Fig. 4b), this overshoot was bigger for fast recovering
mutants (105±0.7%, n¼ 25 for GluA2 WT and 118±3%, n¼ 7,
for GluA2 R675S, peak overshoot reached between 190 and
390ms (Fig. 4c,d), because they are more strongly modulated by
Stargazin, and recover to full-amplitude much faster than the
boost to gating dissipates (Fig. 4b,d). This biphasic behaviour was
not detectable for mutants with slower recovery kinetics, and thus
less-available open states, which showed no change in the rate of
recovery when coexpressed with Stargazin (Fig. 4b and
Supplementary Table 1). Although we could not assess relief of
polyamine block in individual channels, no change in the peak
current G–V relation was detected during the recovery phase
(Supplementary Fig. 5A), suggesting activity-dependent relief of
polyamine block (unlikely at þ 50mV)21, was limited. A
conventional monoexponential ﬁt suggested faster recovery in
the presence of Stargazin, as reported in earlier studies7. However,
when the data were more appropriately ﬁtted using the sum of
two exponentials, including a decaying phase corresponding to
the dissipation of the potentiation from the long pulse, no
signiﬁcant difference in the rate of recovery from desensitization
was observed between GluA2 receptors expressed with Stargazin
and GluA2 receptors alone (Fig. 4e). These results indicate that
Stargazin does not affect the rate of exit of the receptor from the
desensitized state much. As predicted by the model, conditioning
pulses longer than those we normally use led to a progressively
bigger accumulation (at a rate of B2.8±1 s 1) of high-activity
receptors, thus producing an even more profound overshoot
(15±2%, n¼ 12 Fig. 4f,g and Supplementary Fig. 5B,C). The
effect, that we term suprarecovery, can be explained by an
increase in the activity of the receptor-Stargazin complex in an
open state with a higher mean conductance. Strikingly, without
being constrained on these data, the mechanism in Fig. 3a
predicted that suprarecovery should develop at a rate of about
3 s 1 and to about the same extent (Supplementary Fig. 5D).
The slow-augmenting current corresponds to superactivation.
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Figure 2 | Kinetic effects of Stargazin are correlated to open state
availability. (a) Representative traces from GluA2 K761M (left) and GluA2
E713T/Y768R (right) with and without Stargazin evoked by long (top) and
short (bottom) applications of 10mM glutamate. Stargazin signiﬁcantly
affected channel kinetics for the fast recovering mutant A2 K761M
(kdes¼ 150 and 50 s 1; Iss¼ 2 and 30%; kdeact¼ 3,100 and 860 s 1, in the
example traces of receptors without and with Stargazin, respectively) but
had less effect on the slow recovering mutant A2 E713T/Y768R (kdes¼ 170
and 160 s 1; Iss¼ 1 and 7%; kdeact¼ 270 and 260 s 1, in these example
traces without and with Stargazin, respectively). (b) A strong correlation
was observed between the increase in the steady-state current induced by
Stargazin and the recovery rate of the receptors (weighted R2¼0.96,
n¼ 6–34). Fast recovering mutants showed at least 20-fold increase in the
level of steady-state current when coexpressed with Stargazin; in contrast,
mutants with slower recovery displayed only a modest increase in the
steady-state current. Error bars represent s.e.m.
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presence of glutamate, receptors with a less stable desensitized
state (AD2) should show a progressive accumulation in the high
conductance state ARS* (Fig. 5a). Critically, the mechanism
predicted the linear correlation between recovery rate and
fold-increase in steady-state current induced by Stargazin (Figs 2b
and 5b). This correlation occurs because glutamate efﬁcacy is
decreased for mutants with faster recovery. According to the
mechanism we propose, this increases the disparity between
basal gating and channel gating when Stargazin is activated.
Ensuring that detailed balance is obeyed requires mutants with
lower efﬁcacy shift the equilibrium towards activated Stargazin
(the balance between the transitions s*þ and s*–) when the
channel is open.
Indeed, fast recovering receptors such as GluA2 R675S showed a
slow augmentation of the steady-state current during a 5 s
application of glutamate when coexpressed with Stargazin
(increasing by 13±2% with rate 1.6±0.3 s 1, n¼ 10; Fig. 5c).
This increase in the steady-state current is reminiscent of
‘resensitization’, previously observed with g-4, g-7 and g-8
(refs 22,23). In contrast to these studies, but as predicted by our
model, we could observe a slowly augmenting current for GluA2
WT-Stargazin complexes during long application of agonist
(increasing by 8±1% with rate 1.5±0.2 s 1, n¼ 24; Fig. 5c).
The increase in the steady-state current is essentially absent for
receptors with comparatively stable desensitized states, leading to a
further strong correlation, between superactivation and the rate of
recovery from the desensitized state of the receptor, as expected for
our model (R2¼ 0.84; Fig. 3d and Supplementary Fig. 6B). On the
other hand, there was no correlation of superactivation extent to
the magnitude of the current, a surrogate of receptor density
(Supplementary Fig. 6C,D), providing further evidence against any
effects based on association of TARPs into complexes. Finally, we
back-extrapolated the overshoot during suprarecovery (for a
400ms pulse) and found it was very similar in magnitude
(13±2% n¼ 26) to the superactive current, providing further
evidence that the same mechanism underlies both superactivation
and the suprarecovery.
Despite the evident predictive power of the model, we
investigated alternate model geometries, mostly based on the
original model to describe the mutant series17. Models with
different geometries, rate constants and representations of the
mutant series were tested in more than 300 simulations.
We assessed the ability of a given model to reproduce the
following key features of our data and previously published work:
two components in deactivation decay; correlation between
steady-state current increase and recovery rate; larger
steady-state current and Popen; and a left-shift in the steady-
state concentration response curve7,8. Of these, the correlation
between steady-state current increase and recovery rate was the
most sensitive metric, because almost all model geometries
and combinations of rate constants failed to reproduce this
phenomenon.
A key alternate hypothesis for the mechanism of Stargazin
modulation is that Stargazin increases activity by slowing
glutamate unbinding13. However, at the level of a simpliﬁed
model (Supplementary Fig. 7), including a higher conductance
open state, such a scheme failed several of the biophysical criteria
outlined above. First, entry to desensitization was not slowed by
the additional TARP states (Supplementary Fig. 7B), because in
saturating agonist, the desensitization relaxation is not contingent
on the unbinding rate of glutamate. Secondly, such a model only
predicted a hump in recovery curve because of TARPs (Fig. 4)
when recovery was so fast that receptors no longer desensitized at
all (Supplementary Fig. 7F). Third, recovery from desensitization
depends on glutamate dissociation, with more potent ligands
slowing recovery substantially24. Unsurprisingly, in a model
where dissociation is slower from the TARP-active state
(Supplementary Fig. 7F), overall recovery can only be slower,
whereas in experimental observations with Stargazin it is always
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Figure 3 | A model for Stargazin modulation. (a) Simpliﬁed single binding site model of AMPARs without TARPs. Open state is green, shut states are red.
The kinetic behaviour of the mutant series was reproduced by altering the lifetime of the desensitized state AD2 (blue-arrowed rates), which was
compensated by the channel shutting rate (a, pink) to maintain microscopic reversibility. (b) Model including TARPs, with boosted channel opening rate
(bs) in the TARP-active open state only. Other rate constants were as in a. The rate of TARP activation (s*þ , pink) compensated alterations to the channel
shutting rate (a) over the mutant series, to maintain microscopic reversibility. (c) The TARP model predicted larger peak open probability and steady-state
currents, and slower desensitization (Trial #7, see Methods). (d) Concentration response relations were left-shifted for the TARP model, despite equivalent
binding rate constants. (e) The TARP model predicted the more profound slow component in the decay following a 1ms pulse of glutamate for fast
recovering mutants (compare with Fig. 2a).
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Table 1 online). Fourth, and most critically, a model in which
binding principally changed (compare Figs 2b and 5b and
Supplementary Fig. 7G) did not reproduce the positive
correlation between the increase in steady-state current and the
recovery rate for our mutant series. We therefore concluded that,
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Figure 4 | Stargazin induces suprarecovery without changing the rate of recovery from desensitization. (a) Simulated relaxations following equilibrium
desensitization in 10mM glutamate for the model in Fig. 3a. (b) The model from Fig. 3b predicted an overshoot in the recovery for fast recovering
mutants. (c) During recovery, GluA2WTþ Stargazin currents recovered to a higher level than the initial pulse (red diamonds; for the patch shown, 107% of
the initial value; krec¼40 s 1). (d) The overshoot was more profound for the GluA2 R675S mutant (in this example, 120% of the initial peak current;
krec¼84 s 1. (e) Summary of recovery data for GluA2 WTand R675S. A monoexponential ﬁt gave a faster rate of recovery in the presence of Stargazin,
for both GluA2 WT (from 46±4 s 1, n¼ 14 without Stargazin to 90±6 s 1 with Stargazin, n¼ 25) and GluA2 R675S receptors (from 70±8 s 1,
n¼ 15–130±20 s 1, n¼ 15). For biexponential ﬁts, recovery rates with Stargazin were indistinguishable from those of receptors in the absence of Stargazin
(53±3 and 70±8 s 1 for GluA2 WT and GluA2 R675S, respectively). The rates of dissipation of suprarecovery were: 0.95±0.2 and 2.1±0.7 s 1 for
GluA2 WT (n¼ 18) and R675S (n¼ 15), respectively. (f) Increasing the length of the conditioning pulse (from 10 to 1800ms) leads to an increase in the
peak current in the test pulse (maximum of 27%, with ksuper¼ 2.7 s 1, in this example). The interval between pulses was kept constant at 200ms. (g)
Summary of suprarecovery for progressive lengthening of the conditioning pulse for GluA2 WTþ Stargazin (red diamonds, n¼ 6–12) and GluA2 WT
(empty grey diamonds, n¼ 6–8) at an interval of 200ms. Error bars represent s.e.m.
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gating are much better at reproducing the observations than
changes in binding. We cannot rule out much more complicated
combinations of changes induced by Stargazin, but they are not
necessary to describe the observed experimental data.
Removing desensitization boosts superactivation. A report that
removal of desensitization abolishes the slowly augmenting
current concluded that TARPs can reverse desensitization23.
Cyclothiazide (CTZ) blocks desensitization, but does not induce
slow augmentation of TARP-less receptor currents during
long applications of saturating agonist25,26. In contrast, our
mechanism predicts that removing desensitization should make
the TARP-induced increase in the steady-state current during
long glutamate exposures much more profound, because
desensitization otherwise acts as a sink, reducing the fraction of
active receptors (Fig. 6a). In the absence of desensitization, our
mechanism predicted that all receptors are in principle available
to demonstrate the boost to gating due to Stargazin (Fig. 6a).
As predicted, the GluA2 WT-Stargazin complexes showed a
much larger slowly augmenting current when preincubated in
CTZ (increasing by 60, ±10%, n¼ 4; Fig. 6b,e). The same
phenomenon was also revealed for GluA4 WT by CTZ (Fig. 6c,e).
These data indicate that the slow increase of the steady-state
current is not related to the reversal of desensitization, but rather
to occupancy of open states. We thus term this mechanism
‘superactivation’, because complexes become progressively more
active. Consistent with the stronger effects of the TARP g-8 on
AMPA receptor gating12, currents from cotransfection of GluA2
WT with g-8 showed massive superactivation in the presence of
CTZ (220±60% with CTZ, compared with 50±8% when
desensitization is intact, n¼ 11 and 8, respectively; Fig. 6d,e).
With g-8, we could also detect superactivation at negative
potentials, both in the presence and absence of CTZ.
The background, polyamine-sensitive current was on average
20-times larger at negative potential (Supplementary Fig. 8A).
However, the magnitude of superactivation was about twice as
large at –60mV, in line with expected relief of polyamine
block (Supplementary Fig. 8B,E). Magnitude effects are subject
to rundown and other artefacts but critically, the rate of
superactivation was voltage independent for GluA2-g-8
cotransfections (Supplementary Fig. 8D). This result provides
further evidence that voltage effects on AMPAR gating are minor
compared with superactivation, which is robust at both positive
and negative potentials. TARP-induced superactivation was
probably previously missed in some experiments because some
TARPs like g-8 either express poorly or are bad at incorporating
into complexes. Thus modulatory effects were overwhelmed in a
mixed population by receptors with sub-stoichiometric TARP
content. Our data suggest that superactivation is a general
property shared by all TARPs and it is not AMPAR-subunit
dependent, but merely a thermodynamic consequence of the
boosted gating that all TARPs promote. Given the widely held
view that AMPAR gating is modiﬁed by TARPs at synapses11,
and that desensitization is not a prerequisite, superactivation is
likely to occur in vivo.
Superactivation of trains of pulses. To assess if superactivation
occurs in a more physiological situation, we next stimulated
patches with trains of 1ms pulses, mimicking intense synaptic
activity. Such trains depressed responses of wild-type and mutant
receptors, as predicted by our models (Supplementary Fig. 9A,B).
However, following initial depression, peak currents for GluA2
WT receptors coexpressed with Stargazin subsequently recovered
during the train to a higher response that could be maintained
indeﬁnitely (peak currents increased by 10±1% and 8±1%
compared with the extent of the greatest depression, at 200 and
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Figure 5 | Superactivation of AMPA receptors by TARPs. (a) The TARP model predicted slow augmentation of current during long (41 s) glutamate
pulses. (b) Predicted correlation between recovery rate and fold-increase in steady-state current with TARPs (see Fig. 2b). (c) Long application (5 s) of
glutamate to GluA2 WT coexpressed with Stargazin induced a slowly increasing current (11%, k¼ 1.8 s 1, left), which was larger for faster-recovering
mutants (GluA2 R675S, 22%, k¼ 1.5 s 1, right) (d) Correlation between superactivation and recovery rate (Pearson r¼0.91, 95% conﬁdence interval
0.38–0.99, n¼6–34). Error bars represent s.e.m.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10178 ARTICLE
NATURE COMMUNICATIONS | 7:10178 | DOI: 10.1038/ncomms10178 | www.nature.com/naturecommunications 7
mechanism, complexes incorporating the fast recovering mutant
GluA2 R675S and Stargazin exhibited more profound
superactivation during trains (14±4%, n¼ 4 at 200Hz;
Supplementary Fig. 9B). In line with the greater propensity of g-8
to potentiate AMPAR gating, GluA2-g-8 complexes showed
robust superactivation during lower frequency trains, from 50 to
5Hz (50±0.4% n¼ 2, 20±0.1% n¼ 2, 20±0.9% n¼ 4 and
8±0.4% n¼ 2 at 50, 20, 14 and 5Hz respectively; Fig. 7b,c).
The increased activity of the channel during train stimulation
was evident also from the increase in the charge transfer at
the end of the stimulation compared with the beginning (90±15
and  3±4% at 14Hz, P¼ 0.0006, n¼ 8 and 7; 150±80 and
 4±4% at 20Hz, P¼ 0.002, n¼ 10 and 7; 120±35 and  15
±3% at 50Hz, P¼ 0.0003, n¼ 8 and 6, for GluA2þ g-8 and
GluA2 WT, respectively; Fig. 7d). This effect was due to the
lengthening of the current decay and increase of the standing
current (Supplementary Fig. 10), more than any potentiation
of amplitude. Consistent with the expected larger contribution of
superactivation at negative voltage (Supplementary Fig. 8E),
increased charge transfer was evident also at negative potentials,
even though the majority of receptors were not heavily TARPed
enough to be relieved of polyamine block (60±30 and  15
±7% at 14Hz, P¼ 0.01, n¼ 6 and 8; 30±15 and  7±4% at
20Hz, P¼ 0.02, n¼ 8 and 7; 40±10 and  20±5% at 50Hz,
P¼ 0.003, n¼ 7 and 6, for GluA2þ g-8 and GluA2 WT,
respectively; Fig. 7d). Unsurprisingly, wild-type GluA2 without
g-8 exhibited only depression of amplitude and charge transfer
(Fig. 7c,d).
Although our mechanism predicted superactivation and other
previously unheralded properties of TARPed AMPA receptors,
we were concerned that these phenomena might also represent
the association of Stargazin into sub-stoichiometric complexes15.
The relief of polyamine block, being separable from kinetic effects
(Supplementary Fig. 3C), allowed us to assess the average TARP
content of the complexes. Relief of polyamine block in cells
coexpressing GluA2 and Stargazin was less profound than for the
GluA2-Stargazin tandem (Fig. 1b), presumably because
some complexes contain less than four Stargazin molecules. If
Stargazin were recruited into these complexes during prolonged
or repetitive receptor activation, we would expect less block
following stimulation that induced superactivation. Measurement
of the G–V relations, before and after such trains, failed
to reveal differences in polyamine block of similar magnitude to
those between coexpression and tandem (Supplementary Fig. 11).
At the peak of suprarecovery, similar results were obtained
(Supplementary Fig. 5). Further, superactivation was rapidly
inducible and reversible, recurring on a trace-by-trace basis, and
had no dependence on the apparent density of channels
(Supplementary Fig. 6). These ﬁndings suggest that
superactivation is an intrinsic property of the receptor-TARP
complex, and not the result of decreased polyamine block and/or
recruitment of TARPs into complexes.
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Figure 6 | Blocking desensitization enhances TARP-induced superactivation. (a) Removing desensitization from the model (blue traces and scheme, see
Methods) predicted that long glutamate applications should exhibit greatly enhanced superactivation, compared with the model with desensitization intact
(red). (b) Representative traces from GluA2 WTwith Stargazin evoked by 5 s application of glutamate in the absence (ksuper¼ 1.7 s 1, left) and presence
(ksuper¼ 2.5 s 1, right) of CTZ. Abolishing desensitization greatly enhanced superactivation (from 4 to 85% for this trace). (c) When desensitization was
intact, increases in the steady-state current for GluA4-Stargazin complexes in response to long application of 10mM glutamate were barely detectable.
Pre-exposure of the patch to cyclothiazide (CTZ, 100mM) unmasked superactivation (from 0.2%, left panel, to 97%, right panel). Traces pre- and post-
incubation with CTZ are overlaid in the inset. (d) Superactivation by g-8 was also enhanced by CTZ (from 150 to 450% in this example, ksuper¼ 1.7 and
1.8 s 1, in the absence and presence of CTZ, respectively). (e) Bar graph summarising superactivation in the presence and absence of CTZ for
GluA2þ Stargazin (n¼ 24 and 4), GluA4þ Stargazin (n¼ 3) and GluA2þ g-8 (n¼ 8 and 11). Error bars represent s.e.m.
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Discussion
Here, we propose that Stargazin exists in two states: a basal state
that only reduces polyamine block and an active form that is
promoted by receptor opening, and which additionally increases
both channel conductance and glutamate efﬁcacy. We establish
that this simple principle, which allowed us to formulate the ﬁrst
consistent model for the activation of AMPAR-TARP complexes,
has major implications for synaptic transmission. Evidence is
emerging that TARPs promote slow gating modes11,23,27 and our
data demonstrate that switching into the high-activity mode is
driven by receptor activity, perhaps subject to regulation by other
auxiliary subunits23. In contrast to most previously published
work, we examined pure populations of AMPA receptors in
complex with TARPs, and thus were able to ensure that these
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Figure 7 | Train stimulation induces superactivation. (a) 200Hz trains of 1ms pulses of 10mM glutamate, to mimic intense synaptic activity, induced
superactivation of currents from GluA2-Stargazin complexes (in this example, 23%). (b) GluA2 WT receptors coexpressed with g-8 showed
superactivation in response to lower frequency stimulation (20Hz; steady-state potentiation in this example was 31%). (c) Summary of peak current,
normalized to the ﬁrst peak in the train, during 20Hz train stimulation for A2þ g-8 and A2 alone at þ 50 (left panel; n¼8 and 4, respectively) and
 60mV (right panel; n¼ 7 and 4, respectively). (d) Summary of charge transfer increase during train stimulation for A2þ g-8 and A2 alone at þ 50 (left
panel; n¼8–10 and 6–7, respectively) and 60mV (right panel; n¼ 8–10 and 6–7, respectively) recorded at different frequencies. The charge transfer
increase was calculated as the ratio between the change in the charge transfer during the last ﬁve pulse of the train and the change during the ﬁrst ﬁve
pulses (see Methods). A nonparametric randomization test was used; *Po0.05, **Po0.01.
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distinct levels of activity arise from complexes. The unexpected
properties of complexes that we isolated were missed in previous
experiments, probably because these experiments examined
mixtures, which tended to mask the effects of TARPs.
Published effects on mixtures also likely suffered from
variability because they were subject to the variable expression
levels between individual cells.
The model we built depended on our observation that relief of
polyamine block and the kinetic effects of Stargazin are separable,
perhaps because they result from physically distinct interactions.
Our model is agnostic to the sites of interaction between
AMPARs and TARPs, but indicates that conformational changes
alone, and particularly those involved in channel gating, rather
than any change in glutamate afﬁnity (Supplementary Fig. 7), are
sufﬁcient to describe non-equilibrium behaviour of complexes.
Importantly, even though the mutations we used are within the
AMPAR ligand-binding domain, their effects on average activity
in saturating glutamate are the most important factor in their
propensity to alter the effects of Stargazin, rather than any
direct interaction. Notably, this factor may also explain the
GluA-subunit speciﬁcity of modulation20. On the other hand, the
effects on polyamine block seem likely to arise from membrane
interactions28 that are present consistently when complexes
include TARPs, irrespective of mutant kinetics.
The idea that Stargazin has two states explains the two
components in the deactivation decay, as well as the activity-
dependent accumulation of superactive receptors in various
situations. Although other mechanisms producing both short and
long bursts of openings could explain these two components,
single-channel recordings of GluA4 coexpressed with TARPs
reveal that, in addition to long bursts, some channels in the patch
display brief activations just like receptors without TARPs8,19.
This property is explicit in the formulation of our model, because
a layer of states with much higher efﬁcacy of opening
supplements the original model without TARPs. AMPA-type
glutamate receptor-TARP tandem constructs also display two
classes of activity: brief bursts like TARP-less channels and very
long high conductance bursts19, which could correspond to the
two distinct open–closed reactions in our model. Although in
principle, we propose that the complex has two states overall, for
the open channel to have different stabilities in the presence of
TARPs8,19, distinct interactions between TARPs and the
receptor are required in each condition. We cannot exclude the
remote likelihood that this occurs without any conformational
change at all in the TARP, but it appears far more plausible that,
just as the receptor can change conformation between states
driven by ligand-binding, TARPs can change conformation,
promoted by gating of the receptor, to stabilize a superactive form
of the complex.
Despite its obvious physical disconnection from the multiple
subunits of the tetramer, the model we propose has a strong
predictive power and shows the degree to which surprisingly
complex kinetic behaviour can derive from a fairly simple
scheme. While more complex and physically accurate models
were likely to provide more exact descriptions (see below), we
sought to ﬁnd a simple model that could describe existing data
and generate robust predictions that we could test. To what extent
can such a simplistic model be expected to describe AMPA
receptor gating? The single binding site can be thought to
represent one subunit because there is no strong cooperativity of
neurotransmitter binding in AMPA receptors29. We included a
high-efﬁcacy open state with 2.5-fold higher conductance to
describe the generally higher conductance of long bursts in
single-channel recordings8,19. Notably, models that had only a
high-efﬁcacy state, with the same average conductance as the
regular open state, predicted that suprarecovery would be barely
detectable, and absent in wild-type channels (Supplementary
Fig. 12). However, the size of superactivating currents during long
glutamate applications placed an upper limit on this increased
conductance.
The model we propose has some limitations in describing
glutamate receptor activation. Our model does not predict
autoinactivation16,30, perhaps because we only considered
complexes, and autoinactivation might be due to TARP
dissociation. Also, our original scheme cannot replicate the very
rapid dissipation of current for the slow recovering mutants
during trains, (Supplementary Fig. 9) unless desensitization rates
are faster than observed during long pulses. These models with
one binding site cannot capture the subtleties of partially liganded
channels or sublevels, which we suspect are responsible for these
deﬁcits. Such deﬁcits do not detract from the predictive power of
our TARP model with respect to superactivation.
Positive feedback loops are essential for numerous physiological
processes, including the Ferguson reﬂex that initiates childbirth31
and locomotion32. However, such feedback usually encompasses
loops including transcription, post-translational modiﬁcations of
multiple cellular components33, or networks of cells. In contrast,
activity-induced superactivation of AMPAR-TARP complexes is a
much more rapid positive feedback mechanism, entirely contained
within a macromolecular complex. We are unaware of reports of
similar mechanisms within protein complexes, but the fast onset
(within a second) is necessary for the complex to be able to
respond fast enough to have consequences for receptor activity at
synapses. TARPs alter the gating of synaptic AMPA receptors,
producing slow deactivating synaptic currents11,34. According to
our mechanism, it is the small fraction of receptors that are basally
superactive that lengthens the decay of individual synaptic
potentials. The kinetics of AMPARs can contribute to short-term
synaptic plasticity. Receptor desensitization permits short-term
depression at some synapses35–37. On the other hand, facilitation is
exclusively attributed to increased release probability following
presynaptic calcium accumulation, possibly because postsynaptic
mechanisms for short-term potentiation are lacking. This deﬁcit is
notable in the context of target cell-speciﬁc short-term
potentiation, to date ascribed to retrograde signalling to the
presynaptic terminal38. Superactivation of AMPAR-TARP
complexes is a positive feedback mechanism that could in
principle generate short-term potentiation at a purely
postsynaptic locus. We envisage this effect would develop during
repetitive activity within hundreds of milliseconds (Fig. 7), and
dissipate on the timescale ofB1 s (Fig. 4). The expression patterns
of TARPs with differential power to modulate AMPA receptor
gating (for example, Stargazin versus g-8) might balance
superactivation against the frequency of synaptic inputs
according to brain region, or to afford cell speciﬁcity.
Methods
Molecular biology. We used GluA2 and GluA4 ﬂip receptors, unedited at the pore
site (Q-containing) in the pRK vector also expressing eGFP following an
internal ribosomal entry site sequence. Mouse Stargazin was a kind gift from
Susumu Tomita and was subcloned by PCR into the pRK8 vector containing the
non-cytotoxic version of dsRed (dsRed-Max, Addgene plasmid 21718)39 also under
the control of an internal ribosomal entry site. Mouse g-8 (a kind gift from Roger
Nicoll) was subcloned into the same vector. To construct the GluA2-Stargazin
tandem, the C-terminus of GluA2 was directly fused to the N-terminus of Stargazin
(as previously done with GluA1)16. The unique restriction sites EcoRI and XbaI
were inserted by PCR at the 50 and 30 of the GluA2 coding sequence and the stop
codon eliminated. Point mutations were introduced by overlap PCR and conﬁrmed
by double-stranded sequencing. Residues were numbered based on the assumption
that the signal peptide of GluA2 is 21 residues.
Cell culture and electrophysiology. HEK-293 cells (DSMZ, Germany) were
transfected with a total of 3 mg DNA using calcium phosphate. Wild-type and
mutant GluA receptors were cotransfected with Stargazin or g8 at a ratio of 1:2 and
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1:5, respectively. Cells transfected with Stargazin were supplemented with 30 mM
NBQX (Abcam, UK). Cells were recorded 24–48 h after transfection at room
temperature. Outside out patches were voltage-clamped at a holding potential of
either –60 or þ 50mV for kinetic measurements. Currents were sampled at 20 kHz
and low-pass ﬁltered at 10kHz using an Axopatch 200B ampliﬁer (Molecular
Devices, USA) and acquired with Axograph X software (Axograph Scientiﬁc, USA).
The external solution contained: 150mM NaCl, 0.1mM MgCl2, 0.1mM CaCl2 and
5mM HEPES, titrated to pH 7.3 with NaOH, to which we added drugs as required.
The pipette solution contained: 120mM NaCl, 10mM NaF, 0.5mM CaCl2, 5mM
Na4BAPTA, 5mM HEPES and 0.05mM spermine, pH 7.3. Chemicals were
obtained from Carl Roth International (Germany). We applied ligands to outside
out patches via a piezo-driven fast perfusion system (PI, Germany). In the
experiments in which CTZ (100 mM; Hello Bio, UK) was used to reduce receptor
desensitization, we included it in both the wash and glutamate barrels of the
perfusion tool. Typical 10–90% solution exchange times were faster than 300 ms, as
measured from junction potentials at the open tip of the patch pipette.
Data analysis. Receptor desensitization and deactivation were measured by
applying 10mM glutamate for 500 and 1ms, respectively. Both desensitization and
deactivation rates were calculated using a two exponential ﬁtting. Rates constants
are expressed as weighted mean of multiple components. To measure recovery
from desensitization, we used a two-pulse protocol with a variable inter pulse
interval. Recovery data were ﬁtted by a Hodgkin–Huxley-type function:
N ¼ N0 þð1N0Þ  ð1 expð krectÞÞn
where N is the active fraction of receptors at time t following the ﬁrst pulse, N0 is
the active fraction at the end of the conditioning pulse and krec is the rate of
recovery. Recovery data from receptors showing suprarecovery were ﬁtted using
the sum of two exponentials:
N ¼ 1 N0expð krectÞþNsup expð ksuptÞ
where N is the active fraction of receptors, Nsup is the amplitude of superactivation
and ksup is the rate of dissipation of superactivation.
To measure superactivation, we applied glutamate for 5 s and ﬁtted the decaying
and slowly augmenting currents with a triple exponential function (without CTZ)
or the slowly rising current with a one- or two-component exponential (with CTZ).
Where appropriate, multiple components were combined into weighted time
constants for comparisons. Superactivation was deﬁned as the excess steady-state
amplitude over the trough of the current following the initial peak, normalized to
the peak current. This deﬁnition is in principle the same as for resensitization as
previously published, and so values can be directly compared23. For measurements
with CTZ, the initial fast peak corresponding to glutamate activation (within
1–2ms of glutamate application beginning) was taken as the baseline for
superactivation. For measurements of responses paired according to positive and
negative voltage, we excluded one patch where the rundown was so severe that the
initial fast peak was similar in size at negative and positive potential. The charge
transfer during train stimulation was determined by integrating the current trace
over time. The change in the charge transfer (DQ) was deﬁned as follows:
DQ ¼ Q2  Q1ð Þ=Q1
where Q1 was the charge transfer measured during the ﬁrst pulses of the train and
Q2 was the charge transfer measured during the last ﬁve pulses.
At least 5–6 patches from at least three different tranfections were obtained for
each condition, whenever possible. In case of more challenging experiments, at
least three patches were recorded. No data were excluded, except from patches
where recordings were unstable, had excessive rundown or solutions exchange was
slower than 0.5ms. Results are presented as mean±s.e.m. Statistical signiﬁcance
was assessed with nonparametric test, to avoid any unwarranted assumptions about
the distribution of the data. For most comparisons we made a two-tailed, unpaired
Randomization test, with 5,000 to 1 106 runs, using the program RANTEST,
available at https://code.google.com/p/dc-pyps/. ANOVA and linear regression was
done in Graphpad PRISM.
Kinetic modelling. Modelling was done using home-written routines17
incorporated in the PYTHON package Aligator (Analysis of Ligand Gating: trains
and other relaxations; the collection of scripts is available from github.com/
aplested/aligator). The rates were adjusted by hand, paying attention to reproduce
macroscopic rates for wild-type GluA2 including entry to desensitization
(B100 s 1), deactivation (1,000 s 1) and recovery from desensitization
(B20 s 1). The adequacy of particular geometries of rate alterations that maintain
microscopic reversibility is not necessarily detectable in equilibrium measurements,
such as concentration response curves, but is revealed by relaxations. For example,
the relaxation rates from Stargazin active states is determined by the relaxation
from superactivation in recovery protocols, and the activation rates of Stargazin
(for example, s*þ ) was tightly constrained by the development of the slow-
augmenting current during long applications of glutamate. Altering other rate
constants than d2–, d2*–, a and s*þ generally failed to describe previously
published observations, or the correlation between increase in steady-state current
with Stargazin and the recovery rate for our mutant series.
In the ﬁnal simulations based on the model in Fig. 3b, the rate constants
(per second), before adjusting for microscopic reversibility in each trial, were as
follows: s*þ ¼ 15; s*–¼ 3; sþ ¼ 0.07; s–¼ 1; b¼ 8,000; a¼ 3,000; bs¼ 500,000;
d2*þ ¼ 120; d2*–¼ 2; d2þ ¼ 120; d2–¼ 5; d1þ ¼ 300; d1–¼ 25; d0þ ¼ 1;
d0–¼ 3; kþ ¼ 5,000,000; k–¼ 40,000; and kd–¼ 2,500. Applicable rate constants
were the same for the less-complex model without TARPs in Fig. 3a. The
normalized mean conductances of the open states were: state ARs*: 0.4 and ARS*: 1
(except in Supplementary Fig. 11 where the conductances were equal). To model
block of desensitization by CTZ, rates d0þ , d1þ and d2*þ were set to 0.1 s 1.
The kinetics of the GluA2 mutant series can be relatively well described by
changing the lifetime of the deep desensitized state using the model in Fig. 3a. We
thus varied the rates d2– and d2*– as indicated in Table 1.
Trial 0 represented a slow recovering mutant (for example, GluA2 E713T/
Y768R) and Trial 8 a fast recovering mutant (for example, GluA2 K761M). Trial #7
gave the closest approximation to wild-type GluA2. In both mechanisms
(Fig. 3a,b), these changes were compensated by modest alterations in the shutting
rate of the channel (a), consistent with the slower deactivation in slow recovering
mutants17. These manipulations provide a better description that that in our
original report, because the deactivation decay is more accurately described. To
maintain microscopic reversibility, this change was compensated in the TARP
mechanism in Fig. 3b by variation in s*þ , effectively changing the extent to which
receptor activation promoted superactivation across the mutant series. Other
changes, such varying in the TARP-active channel shutting rate separately from the
basal shutting rate (a), or letting s*– or s– vary, failed to reproduce the positive
correlation between increases in steady-state current induced by Stargazin and the
recovery rate, or the hump in the recovery curve.
To model activation by kainate in the absence and presence of TARPs
(Supplementary Fig. 4), we adjusted gating and desensitization rates from the
model in Fig. 3b to mimic the weak agonism and desensitization of kainate
activation of GluA2 (Q)40 as follows (per second): b¼ 1,600; a¼ 30,000;
d2þ ¼ 12; d2–¼ 30; d2*–¼ 12; and d1–¼ 300. The opening rate of the
superactive state (bs) was also reduced ﬁvefold (that is, by the same extent as b) to
maintain the strength of the GluA2-TARP interaction (bs¼ 100,000). Other rates
were the same as in the other simulations, and the corresponding rates in the
absence of TARPs were held the same. The amplitude of single openings of GluA2
(Q) activated by kainate are too small to measure directly, and were previously
estimated at 2.5 pS versus 21 pS for the main glutamate level41. In keeping with this
observation, we reduced the conductance of the kainate-activated, basal open-state
ﬁvefold (normalized: 0.08), while keeping the conductance of the superactive state
the same.
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